Dr. Liguang Lou, born in 1967 in Zhejiang Province, received his master's degree in pharmacology in Henan Medical University in 1993, and Ph.D. in Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 1996. He received his postdoctoral training in Shanghai Institute of Cell Biology, Chinese Academy of Sciences during 1996-1998 and in University of Pittsburgh (USA) during 2000-2002. He is now a PI in Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Dr. Lou’s lab is mainly focusing on anti-cancer drug pharmacology, especially on the discovery of new anti-tumor agents with novel mechanism of action. Through close collaboration with medicinal chemists, he has discovered a number of anti-cancer drug candidates for further development. He was awarded “National outstanding Post-doctor Award” in 2005. He has 10 patents granted and published more than 80 papers. Now he is the standing member of Shanghai Pharmacological Society, and the member of the Committee of Anticancer Drug, Chinese Pharmacological Society. He is also serving a member of editorial board in several journals.

Education 

09/01/1990 - 07/31/1993 M.S., Pharmacology, Henan Medical University, M.S.

09/01/1993 - 07/31/1996 Ph.D. Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

09/01/1996 - 07/31/1998 Postdoctoral fellow, Cell Biology, Shanghai Institute of Cell Biology, Chinese Academy of Sciences 

03/01/2000 - 06/30/2002 Postdoctoral fellow, Pharmacology, University of Pittsburgh, USA

Work Experience 

08/01/1985 - 07/31/1990  Teacher, Department of Anatomy, Zhejiang Quzhou Medical School

08/01/1998 - 02/28/2000 Associate Professor, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences， 

07/01/2002 - 12/01/2002 Associate Professor, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 

01/01/2003 –present Professor, Department of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

1.Study on signaling transduction of tumor cell proliferation via pyridazinone-derivatives as molecular probes，PI，2009.1-2011.12, National Natural Science Foundation.

2.Pharmacological platform for anti-tumor drug innovation，PI，2009.1-2011.12, National Science & Technology Major Project

3.Molecular mechanism of PI3K inhibitor XC-302，PI，2009.1-2011.12, National Natural Science Foundation.

4.Molecular mechanism of YHHU-0632，PI，2012.1-2014.12, National Natural Science Foundation.

5.Design, synthesis, and biological activity of new platinum compounds with DNA-targeting and glycolysis inhibition，Co-PI，2012.1-2014.12, National Natural Science Foundation.

6.The molecular mechanism of a novel HSP90 inhibitor X66，PI，2012.1-2014.12, National Natural Science Foundation.

7.Preclinical study of YHHU-756，PI，2013.1-2015.12, National Science & Technology Major Project.

8.Pharmacological platform for drug innovation，PI，2013.1-2016.12, National Science & Technology Major Project.